Access to Information Orders
Decision Information
NATURE OF THE APPEAL: The Ministry of Health and Long-Term Care (the Ministry) received a request under the Freedom of Information and Protection of Privacy Act (the Act ) for access to information related to a submission for the listing of a product in the Ontario Drug Benefit Formulary (ODB). The requester sought access to: i) relevant correspondence between the affected party or its representatives and the Drug Quality and Therapeutics Committee (DQTC), correspondence between the affected party or its representatives and the ODB, and correspondence between the ODB and the DQTC. ii) cover letter of submission from the affected party or its representatives, ODB acknowledgement letter and any further status letters, acceptance letters, rejection letters and requests for further information. iii) minutes of internal meetings, DQTC meetings, and meetings with the affected party or its representatives. iv) reviewers' comments, including internal and external e-mail. The Ministry granted partial access to one record, but denied access to 45 others in their entirety and one record in part, relying on the exemptions in sections 13(1) (advice or recommendations), 17(1) (third party information), 18(1) (economic and other interests) and 21(1) (invasion of privacy) of the Act. The requester, now the appellant, appealed the Ministry's decision to this office. The Ministry notified two affected parties, the original applicant pharmaceutical company and its consultant, of the access request. After receipt of their representations, the Ministry decided to disclose portions of Records 9 and 11. Accordingly, those portions of the records are no longer at issue. During mediation, the appellant confirmed that he was not seeking access to the names and addresses of the drug reviewers and external consultants. As a result, the personal information in Records 22-31 and the application of section 21(1) are no longer at issue in this appeal. This appeal proceeded to the inquiry stage, and a Notice of Inquiry was sent to the Ministry and two affected parties. Representations were received from the Ministry and counsel for the affected parties. A copy of the Notice, along with the non-confidential portions of the representations of the Ministry and the affected parties, was sent to the appellant. The appellant also made submissions in response to the Notice, which were shared in their entirety, with the Ministry and the affected parties. Both the Ministry and the affected parties then provided additional representations by way of reply. RECORDS: The records at issue are listed in the Index of Records provided by the Ministry with its decision letter. Specifically, the appellant is seeking access to Records 1-8, 10 and 12- 46. The appellant has indicated in its submissions that it is not seeking access to the undisclosed portions of Records 9 and 11, which consist only of the dates of these documents. As a result, Records 9 and 11 are no longer at issue in this appeal. DISCUSSION: THIRD PARTY INFORMATION The Ministry and the affected parties claim the application of the mandatory exemption in section 17(1) to apply to the information contained in Records 1-8, 10, 12-19, 20-21 and 22-31. For a record to qualify for exemption under sections 17(1)(a), (b) or (c), the Ministry and/or the affected party must satisfy each part of the following three-part test: the record must reveal information that is a trade secret or scientific, technical, commercial, financial or labour relations information; and the information must have been supplied to the Ministry in confidence, either implicitly or explicitly; and the prospect of disclosure of the record must give rise to a reasonable expectation that one of the harms specified in (a), (b) or (c) of subsection 17(1) will occur. [Orders 36, P-373, M-29 and M-37] The Court of Appeal for Ontario, in upholding Order P-373, stated: With respect to Part 1 of the test for exemption, the Commissioner adopted a meaning of the terms which is consistent with his previous orders, previous court decisions and dictionary meaning. His interpretation cannot be said to be unreasonable. With respect to Part 2, the records themselves do not reveal any information supplied by the employers on the various forms provided to the WCB. The records had been generated by the WCB based on data supplied by the employers. The Commissioner acted reasonably and in accordance with the language of the statute in determining that disclosure of the records would not reveal information supplied in confidence to the WCB by the employers. Lastly, as to Part 3, the use of the words "detailed and convincing" do not modify the interpretation of the exemption or change the standard of proof. These words simply describe the quality and cogency of the evidence required to satisfy the onus of establishing reasonable expectation of harm. Similar expressions have been used by the Supreme Court of Canada to describe the quality of evidence required to satisfy the burden of proof in civil cases. If the evidence lacks detail and is unconvincing, it fails to satisfy the onus and the information would have to be disclosed. It was the Commissioner's function to weigh the material. Again it cannot be said that the Commissioner acted unreasonably. Nor was it unreasonable for him to conclude that the submissions amounted, at most, to speculation of possible harm. [emphasis added] [ Ontario (Workers' Compensation Board) v. Ontario (Assistant Information and Privacy Commissioner) (1998), 41 O.R. (3d) 464 at 476 (C.A.)] Portions of the representations of the affected parties and the Ministry were not shared with the appellant. These include certain affidavits filed by the affected parties in support of their submissions regarding the application of section 17(1) to the records. I intend to rely on the contents of these submissions, particularly with respect to my discussion of the possible harms which could reasonably be expected to result from the disclosure of the records. Due to the confidential nature of the representations, however, I am unable to refer to them in the text of this order. The basis for my reasons may not, accordingly, be completely set forth in this decision as to do so would result in the disclosure of these confidential representations. When quoting from the representations of the Ministry and the affected parties, I intend only to refer to those portions determined to be non-confidential at the Inquiry stage of the appeals process. Part 1 of the Section 17(1) Test - Type of Information Both the Ministry and the affected parties have made extensive submissions in support of their contention that the records contain information which qualifies as a "trade secret" for the purposes
Decision Content
ORDER PO-2097
Appeal PA-010253-1
Ministry of Health and Long-Term Care
NATURE OF THE APPEAL:
The Ministry of Health and Long-Term Care (the Ministry) received a request under the Freedom of Information and Protection of Privacy Act (the Act) for access to information related to a submission for the listing of a product in the Ontario Drug Benefit Formulary (ODB). The requester sought access to:
i) relevant correspondence between the affected party or its representatives and the Drug Quality and Therapeutics Committee (DQTC), correspondence between the affected party or its representatives and the ODB, and correspondence between the ODB and the DQTC.
ii) cover letter of submission from the affected party or its representatives, ODB acknowledgement letter and any further status letters, acceptance letters, rejection letters and requests for further information.
iii) minutes of internal meetings, DQTC meetings, and meetings with the affected party or its representatives.
iv) reviewers’ comments, including internal and external e-mail.
The Ministry granted partial access to one record, but denied access to 45 others in their entirety and one record in part, relying on the exemptions in sections 13(1) (advice or recommendations), 17(1) (third party information), 18(1) (economic and other interests) and 21(1) (invasion of privacy) of the Act.
The requester, now the appellant, appealed the Ministry’s decision to this office.
The Ministry notified two affected parties, the original applicant pharmaceutical company and its consultant, of the access request. After receipt of their representations, the Ministry decided to disclose portions of Records 9 and 11. Accordingly, those portions of the records are no longer at issue.
During mediation, the appellant confirmed that he was not seeking access to the names and addresses of the drug reviewers and external consultants. As a result, the personal information in Records 22-31 and the application of section 21(1) are no longer at issue in this appeal.
This appeal proceeded to the inquiry stage, and a Notice of Inquiry was sent to the Ministry and two affected parties. Representations were received from the Ministry and counsel for the affected parties. A copy of the Notice, along with the non-confidential portions of the representations of the Ministry and the affected parties, was sent to the appellant. The appellant also made submissions in response to the Notice, which were shared in their entirety, with the Ministry and the affected parties. Both the Ministry and the affected parties then provided additional representations by way of reply.
RECORDS:
The records at issue are listed in the Index of Records provided by the Ministry with its decision letter. Specifically, the appellant is seeking access to Records 1-8, 10 and 12- 46. The appellant has indicated in its submissions that it is not seeking access to the undisclosed portions of Records 9 and 11, which consist only of the dates of these documents. As a result, Records 9 and 11 are no longer at issue in this appeal.
DISCUSSION:
THIRD PARTY INFORMATION
The Ministry and the affected parties claim the application of the mandatory exemption in section 17(1) to apply to the information contained in Records 1-8, 10, 12-19, 20-21 and 22-31. For a record to qualify for exemption under sections 17(1)(a), (b) or (c), the Ministry and/or the affected party must satisfy each part of the following three-part test:
1. the record must reveal information that is a trade secret or scientific, technical, commercial, financial or labour relations information; and
2. the information must have been supplied to the Ministry in confidence, either implicitly or explicitly; and
3. the prospect of disclosure of the record must give rise to a reasonable expectation that one of the harms specified in (a), (b) or (c) of subsection 17(1) will occur.
[Orders 36, P-373, M-29 and M-37]
The Court of Appeal for Ontario, in upholding Order P-373, stated:
With respect to Part 1 of the test for exemption, the Commissioner adopted a meaning of the terms which is consistent with his previous orders, previous court decisions and dictionary meaning. His interpretation cannot be said to be unreasonable. With respect to Part 2, the records themselves do not reveal any information supplied by the employers on the various forms provided to the WCB. The records had been generated by the WCB based on data supplied by the employers. The Commissioner acted reasonably and in accordance with the language of the statute in determining that disclosure of the records would not reveal information supplied in confidence to the WCB by the employers. Lastly, as to Part 3, the use of the words “detailed and convincing” do not modify the interpretation of the exemption or change the standard of proof. These words simply describe the quality and cogency of the evidence required to satisfy the onus of establishing reasonable expectation of harm. Similar expressions have been used by the Supreme Court of Canada to describe the quality of evidence required to satisfy the burden of proof in civil cases. If the evidence lacks detail and is unconvincing, it fails to satisfy the onus and the information would have to be disclosed. It was the Commissioner’s function to weigh the material. Again it cannot be said that the Commissioner acted unreasonably. Nor was it unreasonable for him to conclude that the submissions amounted, at most, to speculation of possible harm. [emphasis added]
[Ontario (Workers’ Compensation Board) v. Ontario (Assistant Information and Privacy Commissioner) (1998), 41 O.R. (3d) 464 at 476 (C.A.)]
Portions of the representations of the affected parties and the Ministry were not shared with the appellant. These include certain affidavits filed by the affected parties in support of their submissions regarding the application of section 17(1) to the records. I intend to rely on the contents of these submissions, particularly with respect to my discussion of the possible harms which could reasonably be expected to result from the disclosure of the records. Due to the confidential nature of the representations, however, I am unable to refer to them in the text of this order. The basis for my reasons may not, accordingly, be completely set forth in this decision as to do so would result in the disclosure of these confidential representations. When quoting from the representations of the Ministry and the affected parties, I intend only to refer to those portions determined to be non-confidential at the Inquiry stage of the appeals process.
Part 1 of the Section 17(1) Test - Type of Information
Both the Ministry and the affected parties have made extensive submissions in support of their contention that the records contain information which qualifies as a “trade secret” for the purposes of section 17(1). They rely on the definition of that term adopted by former Commissioner Tom Wright in Order M-29, set out as follows:
"trade secret" means information including but not limited to a formula, pattern, compilation, programme, method, technique, or process or information contained or embodied in a product, device or mechanism which
(i) is, or may be used in a trade or business,
(ii) is not generally known in that trade or business,
(iii) has economic value from not being generally known, and
(iv) is the subject of efforts that are reasonable under the circumstances to maintain its secrecy.
Essentially, the Ministry and the affected parties submit that the economic information and the methodology employed in obtaining a listing on the Ontario Drug Formulary constitute trade secrets of one of the affected parties.
The appellant, on the other hand, disputes this contention, arguing that “There is no authority for the proposition that strategies and techniques for dealing with government may constitute trade secrets.” The appellant goes on to add that:
Moreover, the strategies and techniques for dealing with government are generally known in the pharmaceutical industry. As a major national and international pharmaceutical company, [the appellant] has considerable experience in making submissions to regulatory authorities, including the DQTC. The overall submission to ODB and the process of gaining Formulary listing is a highly structured process based on the Ontario Drug Benefit Act and Regulations, and the Ontario Guidelines for Drug Submission and Evaluation, which are available and known to the industry as a whole. The strategies and techniques for dealing with government arise within this strict framework and are common to all participants in the industry.
In its reply submissions, the affected party contends that the strategies which pharmaceutical companies employ in making a submission for inclusion in the Formulary “is a closely guarded secret” and a “competitive secret”. It goes on to describe in its confidential representations the actual ingredients of its strategy and the reasons why it takes the position that this information qualifies as a “trade secret” for the purposes of section 17(1).
In my view, the types of information contained in the records at issue in this appeal do not constitute “trade secrets” for the purposes of section 17(1). Despite the evidence tendered by the affected party, I find that the strategies and the methodologies relating to governmental relations which are included in the records are common throughout the pharmaceutical industry and are not in any way unique to the affected parties. The Guidelines referred to by the appellant set the ground rules for the submission of new drug products and describe the process to be employed by all manufacturers. The records do not describe the processes or formulas for the manufacturing of the drug produced by one of the affected parties, rather they relate strictly to the company’s efforts to have the drug included in the Ontario Formulary. In my view, this information cannot qualify as a “trade secret” for the purpose of section 17(1) as it is generally known in the pharmaceutical industry and is common to all manufacturers.
The Ministry and the affected parties also submit that the records contain information which qualifies as “commercial”, “scientific”, “technical” and “financial” information within the meaning of section 17(1). These terms have been defined in previous orders as follows:
Scientific Information
Scientific information is information belonging to an organized field of knowledge in either the natural, biological or social sciences or mathematics. In addition, for information to be characterized as scientific, it must relate to the observation and testing of specific hypothesis or conclusions and be undertaken by an expert in the field. Finally, scientific information must be given a meaning separate from technical information which also appears in section 17(1)(a) of the Act. [Order P-454]
Technical Information
Technical information is information belonging to an organized field of knowledge which would fall under the general categories of applied sciences or mechanical arts. Examples of these fields would include architecture, engineering or electronics. While, admittedly, it is difficult to define technical information in a precise fashion, it will usually involve information prepared by a professional in the field and describe the construction, operation or maintenance of a structure, process, equipment or thing. Finally, technical information must be given a meaning separate from scientific information which also appears in section 17(1)(a) of the Act. [Order P-454]
Commercial Information
Commercial information is information which relates solely to the buying, selling or exchange of merchandise or services. The term "commercial" information can apply to both profit-making enterprises and non-profit organizations, and has equal application to both large and small enterprises. [Order P-493]
Financial Information
The term refers to information relating to money and its use or distribution and must contain or refer to specific data. Examples include cost accounting method, pricing practices, profit and loss data, overhead and operating costs. [Orders P-47, P-87, P-113, P-228, P-295 and P-394]
One of the affected parties relies on the findings of former Commissioner Sidney B. Linden in Order 68 and Assistant Commissioner Tom Mitchinson in Order P-284 where it was held that information relating to a Formulary submission qualified as “scientific”, “financial” and “commercial” information for the purposes of section 17(1). Specifically, it argues that Records 4, 15, 17 and 19 also contain scientific information relating to its product. It indicates that other records contain information relating to the marketing of this product and that this portion of the records qualifies as “commercial” information. Further, it submits that other records contain information which qualifies as “financial” information within the meaning of section 17(1).
The appellant submits that any “scientific “ information relating to the affected party’s product “is already captured in the Product Monograph approved by Health Canada and generally available to health practitioners and the public.” It argues that any information relating to the safety or efficacy of this product, including clinical reviews, is already widely available. Accordingly, it submits that if the records at issue contain such information, it ought not to qualify for exemption under section 17(1) as it is already publicly available. The appellant also submits that records submitted in support of an application for a Formulary listing do not include information relating to the applicant’s financial position or marketing strategies and, therefore, the records do not contain information which qualifies as either financial or commercial information.
Records 1, 3, 6 and 7, which are each entitled “Notice of Drug Submission Status”, were sent to the affected party by the Director of the Ministry’s Drug Programs Branch. In my view, these records do not contain information which qualifies as commercial, financial, scientific or trade secret information for the purposes of section 17(1). As such, they do not qualify for exemption under this section. As this is the only exemption claimed for these records, I will order that they be disclosed to the appellant.
Records 2, 4, 5, 8, 10, 12-19, 20-21 and 22-31 contain information which relates to the selling of merchandise, the affected party’s product. The records relate directly to the efforts of the affected party to market this product through its inclusion in the Ontario Formulary. I find that these records contain “commercial information” within the meaning of section 17(1). Further, I find that discrete portions of these records also contain information which qualifies as “financial” and “scientific” information for the purposes of section 17(1). As a result, I find that the first part of the section 17(1) test has been satisfied with respect to Records 2, 4, 5, 8, 10, 12-19, 20-21 and 22-31.
Part Two of the Section 17(1) Test - Supplied in Confidence
The Ministry and the affected parties submit that the information contained in Records 2, 4, 5, 8, 10, 12-19, 20-21 and 22-31 was provided to the Ministry in confidence by the affected parties.
Supplied
The “supplied” requirement of the Part 2 test reflects the purpose in this exemption, that being the protection of the informational assets of a third party. The authors of the William Commission report (Public Government for Private People: The Report of the Commission on Freedom of Information and Individual Privacy 1980, vol. 2 (Toronto: Queen’s Printer, 1980)) made the following comments about this purpose:
. . . [T]he [proposed] exemption is restricted to information “obtained from a person” in accord with the provisions of the U.S. act and the Australian Minority Report Bill, so as to indicate clearly that the exemption is designed to protect the informational assets of non-governmental parties rather than information relating to commercial matters generated by government itself. The fact that the commercial information derives from a non-governmental source is a clear and objective standard signaling that consideration should be given to the value accorded to the information by the supplier. Information from an outside source may, of course, be recorded in a document prepared by a governmental institution. It is the original source of the information that is the critical consideration: thus, a document entirely written by a public servant would be exempt to the extent that it contained information of the requisite kind. (pp. 312-315) [my emphasis]
In its confidential representations, the Ministry sets out in the form of a table the circumstances surrounding the supply of each of the records to which it has applied section 17(1). Based on the contents of this submission, I find that the information contained in each of Records 2, 4, 5, 8, 10, 12-19, 20-21 and 27-31 were supplied by the affected parties to the Ministry within the meaning of section 17(1).
However, Records 22 to 26 are copies of letters sent to the members of the DQTC requesting their reviews of one of the affected parties’ application for the listing of its product on the Formulary. I find that these documents do not contain information which was “supplied” to the Ministry by the affected parties for the purposes of section 17(1). The letters serve only to request the reviewers comments and do not include the actual submission of the affected parties. In order to qualify for exemption under section 17(1), the information must have been supplied by the third party to the institution. In the case of Records 22 to 26, the information contained in these records originated with the Ministry and not the affected parties.
In Confidence
In regards to whether the information was supplied in confidence, part two of the test for exemption under section 17(1) requires the demonstration of a reasonable expectation of confidentiality on the part of the supplier at the time the information was provided. It is not sufficient that the business organization had an expectation of confidentiality with respect to the information supplied to the institution. Such an expectation must have been reasonable, and must have an objective basis. The expectation of confidentiality may have arisen implicitly or explicitly. [Order M-169]
In determining whether an expectation of confidentiality is based on reasonable and objective grounds, it is necessary to consider all the circumstances of the case, including whether the information was:
(1) Communicated to the institution on the basis that it was confidential and that it was to be kept confidential.
(2) Treated consistently in a manner that indicates a concern for its protection from disclosure by the affected person prior to being communicated to the government organization.
(3) Not otherwise disclosed or available from sources to which the public has access.
(4) Prepared for a purpose which would not entail disclosure.
[Order P-561]
Representations of the Ministry and the Affected Parties
The Ministry submits that Records 1 to 8 consist of confidential correspondence between one of the affected parties and its Drug Programs Branch (the DPB) which was “supplied implicitly in confidence”, owing to its highly sensitive strategic and proprietary nature. It states that such information is treated as “highly confidential” by the DPB and the affected party. It goes on to submit that Records 10 and 12-19 consist of confidential correspondence submitted by one of the affected parties to the Ministry and that the information they contain includes:
- communications relating to the submission of [the affected party’s product] for inclusion in the Formulary;
- pharmacoeconomic and other background information relating to [the product];
- information relating to the safety and efficacy of [the product];
- strategies used by [the affected party] in dealing with the Government with respect to its drug submissions; and
- trade secrets and highly sensitive commercial and marketing information regarding [the product].
In support of its contention that the records were submitted with an explicit expectation that they would be treated in a confidential manner, the Ministry points out that Records 14 and 15 are clearly labelled “confidential and urgent”.
The Ministry also submits that Records 20 and 21 contain financial and economic projections for the sale of the drug product. With respect to Records 22 to 31, the Ministry submits that these consist of confidential correspondence between the DQTC reviewers and the DPB. In particular, Records 27 to 31 are the actual clinical and pharmacoeconomic reports on the drug product under consideration as prepared by the DQTC reviewers.
The affected parties submit that all of the information contained in Records 1-8, 10, 12-19, 20-21 and 22-31 was supplied with an implicit expectation that they would be treated confidentially. The affidavit materials filed by the affected parties speak directly to this issue and I am unable to refer to them specifically in this order. The affected parties submit that in their experience, the Ministry routinely considers material contained in or related to a submission for listing a product on the Formulary to be confidential, and that they share this view. The Ontario Guidelines for Drug Submission and Evaluation prepared by the Ministry in September 2000 support the affected parties’ contention as it states, at page II-5, that:
All other submission information will continue to be held in confidence by the Ministry.
Representations of the Appellant
The appellant acknowledges that the records at issue contain information which was supplied by the affected parties to the Ministry. It submits, however, that the affected parties cannot have a reasonable expectation that the information they provide will be kept confidential. The appellant submits that:
[it] recognizes the critical public purpose of the regulatory process and expects transparency in that process. The regulatory process necessarily and rightfully subjects participants to some measure of public scrutiny.
. . .
The argument that a pharmaceutical company which applied to have its drug listed on the Formulary, to permit it to be prescribed to and paid for by Ontario’s citizens, has a right to confidentiality in safety and efficacy information filed in support of its application is manifestly unreasonable.
Findings with Respect to the “In Confidence”Aspect of Part II of the Test
I find that the information in Records 2, 4, 5, 8, 10, 11, 12, 13, 14, 15, 16, 17, 18 and 19 was provided to the Ministry by one of the affected parties with a reasonably-held expectation of confidentiality. The records themselves speak to the confidential nature of the information which they contain and I accept the affected party’s submissions on this aspect of the section 17(1) test.
The information in Records 20 and 21 was provided to the Ministry by the other affected party. Again, the contents of the records themselves indicate the confidential nature of the information which they contain. I find that Records 20 and 21 were supplied to the Ministry by the affected party with a reasonably-held expectation that they would be treated confidentially.
Records 27-31 are the actual reviews undertaken by the DQTC reviewers charged with providing their professional comments on the affected party’s product. I find that these records contain detailed information which originated with the submissions made by the affected party. The disclosure of these records would, therefore, reveal information which had been supplied with an expectation of confidentiality by the affected parties. Accordingly, I find that I have been provided with sufficient evidence to make a finding that these records contain information which was supplied to the Ministry in confidence for the purposes of section 17(1).
Part Three of the Section 17(1) Test – Harms
Introduction
To discharge the burden of proof under the third part of the test, the parties opposing disclosure, in this case the Ministry and the affected parties, must present evidence that is detailed and convincing, and must describe a set of facts and circumstances that could lead to a reasonable expectation that one or more of the harms described in section 17(1) would occur if the information was disclosed. [Order P-373]
The words “could reasonably be expected to” appear in the preamble of section 17(1), as well as in several other exemptions under the Act dealing with a wide variety of anticipated “harms”. In the case of most of these exemptions, in order to establish that the particular harm in question “could reasonably be expected” to result from disclosure of a record, the party with the burden of proof must provide “detailed and convincing” evidence to establish a “reasonable expectation of probable harm” [see Order P‑373, two court decisions on judicial review of that order in Ontario (Workers’ Compensation Board) v. Ontario (Assistant Information and Privacy Commissioner) (1998), 41 O.R. (3d) 464 at 476 (C.A.), reversing (1995), 23 O.R. (3d) 31 at 40 (Div. Ct.), and Ontario (Minister of Labour) v. Big Canoe, [1999] O.J. No. 4560 (C.A.), affirming (June 2, 1998), Toronto Doc. 28/98 (Div. Ct.)]. [Orders PO-1745 and PO-1747]
Representations of the Ministry
The Ministry submitted detailed representations with respect to the harms issue, referring to each individual record which it claims is subject to the exemption in section 17(1). Portions of those representations were not shared with the appellant due to concerns about confidentiality and, as indicated above, I am unable to refer to them in this decision.
Section 17(1)(a)
Essentially, the Ministry takes the position that prejudice to the affected party’s competitive position could reasonably be expected to occur should the records at issue be disclosed. It argues that:
Any information disclosed relating to scientific testing, manufacturing procedures and methods, sales or marketing projections, etc., would assist a competitor to bring a drug similar to [the affected party’s product] onto the market even more quickly than would otherwise be the case. This would have an extremely adverse affect on the competitive position of [the affected party] in the pharmaceutical marketplace. In turn, the detriment suffered by [the affected party] would translate to a negative effect on the Ministry, since the listing of [the affected party’s] product would result in substantial cost savings to the MOHLTC. [more elucidation on this point is provided in the Ministry’s decision of the application of section 18(1) below]
The Ministry relies on the decision of this office in Order 47 in support of its contention that the disclosure of information relating to the pricing of a drug product by a manufacturer would allow competitors to “calculate future price submissions and pricing structures” to the detriment of the original manufacturer. It also submits that some of the records contain information which, if taken out of context, could be used by competitors to the detriment of the affected party in the marketing of drug products similar to that under discussion in the records at issue in this appeal. It also indicates that the disclosure of the information in the records which relates to the strategies and techniques employed by the affected party in successfully having its product listed in the Formulary could reasonably be expected to be exploited by its competitors in their applications for other drug products.
Insofar as the information relating to the financial impact of the inclusion of the affected party’s product on the Formulary is concerned, the Ministry submits that the affected party would suffer real economic loss in its market should this information be disclosed. The Ministry points out that the pharmaceutical industry is particularly competitive as the stakes are so high. Potential sales and profits are substantial to a firm which is successful in having a product listed on the Formulary, particularly for a general as opposed to a limited use listing. For this reason, the manufacturers of drug products jealously guard the information they provide to the Ministry when seeking a listing.
It further submits that the disclosure of the clinical reviews of the drug product described at Records 27-29:
. . . could expose strengths and weaknesses of [the affected party’s] new drug to its competitors. This would obviously benefit competitors of [the affected party], while having a detrimental and prejudicial effect on the competitive position of [the affected party] itself.
By way of summary, I find that Records 33, 36, 37, 39, 40, 41, 42, 43 and 44 qualify for exemption under section 13(1). The information contained in Records 34, 35, 38, 45 and 46 does not, however, fall within the ambit of this exemption and I will, accordingly, order that it be disclosed.
ORDER:
1. I order the Ministry to disclose Records 1, 3, 6, 7, 12, 16, 19, 22 to 26, 34, 35, 38, 45 and 46 to the appellant by providing him with copies no later than February 19, 2003 (35 days) but not before February 14, 2003 (30 days).
2. I uphold the Ministry’s decision not to disclose Records 2, 4, 5, 8, 10, 13, 14, 15, 17, 18, 20, 21, 27 to 31, 32, 33, 36, 37, 39, 40, 41, 42, 43 and 44.
3. In order to verify compliance with the terms of Order Provision 1, I reserve the right to require the Ministry to provide me with a copy of the records which are disclosed to the appellant.
Original signed by: January 15, 2003